Abstract
Background
Transthoracic esophagectomy (TTE) with lymphadenectomy represents the gold standard of operative approaches to esophageal cancer. The TTE procedure carries significant operative risk, particularly in patients with co-morbidities, and the possible oncologic benefit of a mediastinal lymph node dissection in certain subgroups of patients with esophageal cancer is controversial. Transhiatal esophagectomy (THE), which avoids a thoracotomy, may reduce morbidity and mortality below levels seen with TTE, and there is no proof from randomized studies of any oncologic inferiority to TTE in patients with early tumors. Accordingly, the selective use of THE has increased in our high-volume center in recent years, and this study audits that experience over the last decade
Methods
Between 2000 and 2009 inclusive, 584 patients were treated surgically with curative intent. The standard operative approach in our unit is en bloc TTE, and THE represents 5.5% overall, and 11.1% in the second 5-year period (2004–2009), compared with 2% previously. The present study details the selection of these cases (n = 32) treated with THE and their outcomes, as well as the outcomes in the TTE (n = 438) group
Result
Transhiatal esophagectomy was used for early stage carcinoma (n = 18) and for patients of advanced age who also had co-morbidities (n = 14). Patients undergoing THE were significantly older (68.46 versus 63.07 years of age; p = 0.002), and were at higher operative risk based on ASA grade (grade 3: 53.1% versus 17.3%; p < 0.001), compared with TTE patients. The THE cohort also included more patients with early cancers compared with the TTE cohort (56.3% versus 17.6%; p < 0.001). There were no differences in R0 resection rates for patients with early tumors or advanced co-morbidity. Nodal yields were lower in THE patients (p = 0.005). The overall complication rate was lower in the THE group (31.6% versus 44.2%; p = 0.021), and there were no postoperative deaths in the transhiatal group, whereas the in-hospital mortality rate for the TTE group was 3% (p < 0.001). Disease-specific survival was equivalent with each approach.
Conclusions
Transhiatal esophagectomy has a role in a pragmatic individualized approach to esophageal cancer. As an alternative to a standardized en bloc transthoracic esophagectomy, the transhiatal approach may be suitable for patients with predicted node-negative cancers or those with resectable disease who are not candidates for TTE because of co-morbidity.
Similar content being viewed by others
References
Portale G, Hagen JA, Peters JH et al (2006) Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients. J Am Coll Surg 202:588–596
Altorki N, Kent M, Ferrara RN et al (2002) Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg 236:177–183
Orringer MB, Marshall B, Chang AC et al (2007) Two thousand transhiatal esophagectomies. Ann Surg 246:363–374
Davies AR, Forshaw MJ, Khan AA et al (2008) Transhiatal esophagectomy in a high volume institution. World J Surg Oncol 6:88
Hulscher JB, van Sandick JW, de Boer AG et al (2002) Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 347:1662–1669
Omloo JM, Lagarde SM, Hulscher JB et al (2007) Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomised clinical trial. Ann Surg 246:992–1000
Chu K-M, Law SYK, Fok M et al (1997) A prospective randomized comparison of transhiatal and transthoracic resection for lower-third esophageal carcinoma. Am J Surg 174:320–324
Goldminc M, Maddern G, Le Prise E et al (1993) Esophagectomy by transhiatal approach or thoracotomy: a prospective randomized trial. Br J Surg 80:367–370
Peyre CG, Hagen JA, De Meester SR et al (2008) The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg 248:549–556
Reynolds JV, Muldoon C, Hollywood D et al (2007) Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg 245:707–716
American Joint Cancer Commission (2010) AJCC Cancer Staging Manual, 7th edn. Springer, New York
Fearon K, Strasser F, Anker SD et al (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12:489–495
Enzinger PC, Mayer RJ (2003) Esophageal cancer. N Engl J Med 349:2241–2252
Bedenne L, Michel P, Bouche O et al (2007) Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25:1160–1168
Luketich JD, Alvero-Rivera M, Buaneaventura PO et al (2003) Minimally invasive esophagectomy: outcomes in 222 patients. Ann Surg 238:486–494
Johannsen J, DeMeester TR, Hagen JA et al (2004) En bloc vs transhiatal esophagectomy for stage T3 N1 adenocarcinoma of the distal esophagus. Arch Surg 139:627–633
Herrera L (2010) Extent of lymphadenectomy in esophageal cancer: how many lymph nodes is enough? Ann Surg Oncol 17:676–678
Leers JM, De Meester SR, Chan N et al (2009) Clinical characteristics, biologic behaviour, and survival after esophagectomy are similar for adenocarcinoma of the gastroesophageal junction and the distal esophagus. J Thorac Cardiovasc Surg 138:594–602
Acknowledgment
This work is funded by an Irish Cancer Society Research scholarship.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Donohoe, C.L., O’Farrell, N.J., Ravi, N. et al. Evidence-Based Selective Application of Transhiatal Esophagectomy in a High-Volume Esophageal Center. World J Surg 36, 98–103 (2012). https://doi.org/10.1007/s00268-011-1307-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00268-011-1307-0